1 Introduction

Coronaviruses belong to the family Coronaviridae, and the name is derived from the Latin word corona, meaning crown. This refers to the distinctive structure of the virus envelope, containing projections that give it the appearance of a crown. Coronaviruses (CoVs) infecting humans can cause a wide range of respiratory, hepatic, gastrointestinal and neurological diseases, and have been identified in two genera: alpha- and beta-coronaviruses. Among the beta CoVs, Severe Acute Respiratory Syndrome-CoV (SARS-CoV) and Middle East Respiratory Syndrome-CoV (MERS-CoV) emerged in the early 2000s in humans.

The genome of the novel coronavirus that was reported in Wuhan, China, in December 2019, taxonomically designated SARS-CoV-2 is a single-stranded positive-sense RNA, about 30 kb in length, and is among the largest-known RNA viruses. The disease caused by SARS-CoV-2, officially named Coronavirus Disease-2019 (COVID-19) by the World Health Organization (WHO), and declared a public health emergency of international concern by late January 2020, leads to lower respiratory distress with a global mortality rate of 5–6% on average. Most infected persons have mild respiratory symptoms; however, some develop severe respiratory distress and death occurs due to multiple organ complications (table 1).

Table 1 Manifestations of COVID-19 beyond respiratory distress
Full size table

2 Neurological manifestations of SARS-CoV-2 infection

The COVID-19 pandemic quickly spread to almost all the continents last year, but we have just begun to understand the complexities and manifestations of this syndrome. Although there is still dearth of available medical literature detailing the neurologic manifestations in patients suffering from SARS-CoV-2 infection, crucial information was reported from patients undergoing treatment in China and elsewhere in the world (Ellul et al. 2020). It was a common notion that Coronaviruses do not impact the brain or nervous system, but time and again since the SARS outbreak this perception has been proven wrong (Matías-Guiu et al. 2020a). Out of the total number of SARS-CoV-2 patients requiring hospitalization, 10–20% require Intensive care unit (ICU) admission and subsequently required mechanical ventilation support (Borges do Nascimento et al. 2020). Although the reported clinical symptoms of patients suffering from the viral infection include fever, dry cough and fatigue, there is increasing evidence of neurological involvement in some late-stage cases (Cascella et al. 2020; Aaroe et al. 2020). However, little can be done after a patient reaches extant neurological damage. This makes it necessary to detect the neuronal damage in early stages of the disease. In one of the reported cases during the SARS epidemic, the SARS-CoV virus was isolated from the brain of a patient exhibiting neurological deficit after 28 days of infection (Baig 2020). Similar results were observed from brain autopsies of COVID-19 patients where the brain tissue was edematous with degenerated neurons (Matías-Guiu et al. 2020b). Studies from the SARS outbreak have demonstrated that SARS-CoV can target the CNS and the brain. The immunohistochemistry studies performed on the brain autopsies of SARS patients demonstrate edema with neuronal degeneration and electron micrographs confirmed viral infection of the neurons. This raises the possibility of increased number of patients with neurological manifestations during the COVID-19 pandemic. A retrospective study from the frontline in Wuhan where the pandemic began revealed that out of 214 patients studied, 36.4% displayed various neurologic manifestations involving CNS, PNS, and skeletal muscles (Mao et al. 2020a). CNS-based neurological manifestations included dizziness, headache, altered consciousness levels such as stupor, coma and delirium, ataxia, acute cerebrovascular disease and seizure. On the other hand, PNS-based neurological manifestations included taste, smell and vision impairment and nerve pain (Mao et al. 2020a). In another unique study of its kind, a Chinese male patient infected with SARS-CoV-2 and having neurological manifestations was found to have the virus in cerebrospinal fluid (CSF) (Moriguchi et al. 2020). Although the lungs are the most affected organ in SARS-CoV-2 infection due to the abundance of ACE-2 in alveolar cells, there is an increasing body of evidence that this virus affects the brain to a great extent that it will leave severe long-lasting impact. It is believed that the neuro-invasive potential of the virus could be responsible for the abnormal respiratory response. Indeed, it was shown that coronavirus could reach the brainstem through a connected synapse (Iroegbu et al. 2020). The brain’s medulla oblongata and lower brain stem control the respiratory reflex, and therefore impaired cough and gag reflex may be an early sign of neurologic manifestation during the disease. Additionally, there are reports of increasing number of patients showing intracerebral haemorrhages (Iroegbu et al. 2020). It is yet to be demonstrated whether these hemorrhages are a result of uncontrolled hypertension due to interaction of SARS-CoV-2 with ACE-2 receptor. Further studies will help determine if hypertensive encephalopathy could be considered an early sign of impending neurological manifestations in COVID-19 patients. Therefore, it is critical to study the underlying mechanisms of neuronal damage in SARS-CoV-2 infection.

3 Pathogenic strategy of SARS-CoV-2 and CNS tropism

The spike protein (S) of the novel coronavirus SARS-CoV-2 exhibits 73–76% receptor binding domain similarity with that of the earlier SARS-CoV. This high level of similarity indicates that SARS-CoV-2 potentially binds to host cell membrane through the same host receptors as SARS-CoV, namely the angiotensin-converting enzyme 2 (ACE2). Moreover, the ACE2 binding affinity of human host cells with SARS-CoV-2 spike protein is revealed to be 10–20 fold higher than SARS-CoV (Wrapp et al. 2020). A serine protease TMPRSS2 may be required for S protein priming. Comparison of the SARS-CoV and SARS-CoV-2 receptor-binding-motifs shows no evidence of deletions or insertions, confirming the role of ACE2 and TMPRSS2 in COVID-19 (Wan et al. 2020; Hoffmann et al. 2020). An over-expression of TMPRSS2 and ACE2 receptors was observed in SARS-CoV-infected tissues (Gupta et al. 2020b; Zhang et al. 2020). Exploring the expression patterns of these receptors in infected tissues of COVID-19 patients may yield similar results.

ACE2 receptor in humans is expressed in a variety of organs such as lungs, intestine, brain, heart, liver, lymphoma cells, capillary endothelium, and testis (Palasca et al. 2018). All these organs should therefore be considered as potential targets of COVID-19. The symptoms of COVID-19 indicate that lungs, brain, and intestines may be affected. ACE2 expression in lungs is mainly in the alveolar type 2 (AT2) cells, followed by low level expression in AT1 and fibroblasts cells. AT2 cells were found to be the most affected during the SARS-CoV infection, and this cell type may well be the main target for COVID-19. Any change in expression level of ACE2 in AT2 can thus affect the severity of disease progression (Zhang et al. 2020).

Most β-coronaviruses that infect humans, including SARS-CoV and MERS have demonstrated neuroinvasive potential. A SARS-CoV-2 isolate from Germany was demonstrated to infect neurons in 3D human brain organoids, and was associated with Tau abnormalities and neuronal cell death (Ramani et al. 2020). In human SARS-CoV-2 infection, fatality appears to be due to widespread dysregulation of homeostasis caused by lung, kidney, cardiac and circulatory damage. However, cerebral damage may complicate SARS-CoV-2 infections. Another study found that among SARS-CoV-2 infected patients in Wuhan, 36.4% demonstrated neurological manifestations such as headache, dizziness and epilepsy (Mao et al. 2020a). The virus has also been detected in the cerebrospinal fluid of some patients (Moriguchi et al. 2020). A case study published on 31 March 2020 reported a COVID-19 patient developing acute haemorrhagic necrotizing encephalopathy (Poyiadji et al. 2020). Although the association of cerebral damage to SARS-CoV-2 infection has not been confirmed yet, this type of rare encephalopathy has been previously linked to other viral infections such as influenza (figure 1).

Figure 1
figure 1

Most commonly reported SARS-CoV-2 infected regions of the brain, marked and colour-coded based on the probability of infection and severity. Regions of the brain that have a high probability of being severely infected by SARS-CoV-2 include olfactory bulb, medulla, nucleus tractus solitaries (NTS) and rostral ventrolateral medulla (RVLM), indicated by red asterisk. Hippocampus and cerebrum are other regions likely to be infected by the virus (dark blue), while cerebellum, basal ganglia and corpus callosum (light blue) are not likely to be infected.

Full size image

SARS-CoV-2 may cause neurological damage by a variety of mechanisms. They may enter the CNS either directly through the olfactory nerve, or through the systemic circulation by breaching the blood-brain and blood-retinal barriers. After gaining entry into the CNS, these viruses may lead to neuronal damage as a result of encephalitis (inflammation in the brain), encephalopathy (cerebral oedema), or cerebrovascular events (ischaemic injury due to cytokine cascades).The ACE2 receptor is present on glia as well as neurons. Hence, SARS-CoV-2 can potentially bind to ACE2 on glial cells in the CNS via spike proteins.

4 SARS CoV- 2 and the blood-brain barrier

The BBB is made up of highly specialized cells such as vascular endothelial cells, pericytes, astrocytes, microglia and neurons which act in concert to prevent the entry of bacteria, viruses, immune cells and soluble molecules into the central nervous system (CNS) (Keaney and Campbell 2015). If viruses succeed in crossing this barrier and infect the CNS, the BBB can open in a regulated manner to allow leukocyte transmigration into the CNS, so that virus-infected cells, dead cells and debris can be cleared (Reynolds and Mahajan 2021). Recent studies show that significant upregulation of inflammatory cytokines such as TNF-α, IL-6, IL-10, and IL-23 could occur in COVID-19 patients and that such a ‘cytokine storm’ could be a crucial factor in disrupting the BBB (Reynolds and Mahajan 2021; Alquisiras-Burgos et al. 2021).

Neurotropic viruses that cause encephalopathy or encephalitis contribute significantly to global mortality and morbidity. These infections can lead to mild cognitive impairment and memory loss, and in some cases may even result in permanent CNS damage and death (Wu et al. 2020b). However, neuroinvasion occurs only in a small percentage of persons infected with neurotropic viruses. It is believed that host-pathogen interactions at the BBB may play a role in preventing these viruses from gaining access to glia and neurons of the CNS (Wu et al. 2020b).

SARS-CoV-2 spike protein has high affinity for the ACE2 protein which is expressed on the capillary endothelial cells, among other cell types. The virus may infect the capillary endothelium, and budding of virus particles from endothelial cells may damage the BBB leading to subsequent entry of the virus from systemic circulation into the brain. Indeed, it was recently reported that S1 protein of SARS-CoV-2 crosses the BBB in mice (Rhea et al. 2021).

5 SARS CoV-2 and the olfactory route

ACE2 receptors in the brain are expressed in neurons and glia in different regions like the olfactory bulb, cortex, hippocampus and major nuclei including nucleus tractus solitaries (NTS), rostral ventrolateral medulla (RVLM) and paraventricular nucleus. It is also highly expressed in brain regions involved in cardiovascular regulation (Wu et al. 2020b). Experiments in mouse models expressing human ACE2 receptors and subsequent exposure to SARS-CoV suggests that the olfactory pathway may be a means of virus entry to the brain, and the olfactory bulb may be the primary point of infection. This model also suggests a transneuronal spread of coronaviruses from the olfactory bulb to the rest of the brain. In the mice that survived infection, loss of neurons was detected in infected brain regions (Netland et al. 2008).

An increase in clinical results showing loss of olfaction as an early symptom of COVID-19 patients indicates that the infection may proceed through the olfactory pathway (Eliezer et al. 2020).The olfactory ensheathing glial cells (OEC), with high ACE2 expression or the olfactory receptors neurons (ORN) with mosaic expression of TMPRSS2, may be the first sites of infection in this pathway. Both these cell types are present in the olfactory epithelium (OE), making the OE a potential viral reservoir (Butowt and Bilinska 2020). Most β-coronaviruses such as MERS and SARS show a similar mechanism of infection, based on which a plausible mechanism can be extrapolated for SARS-CoV-2 (Eliezer et al. 2020):The viruses bud from the endoplasmic reticulum, pass through Golgi intermediate compartments, and assemble as vesicles. The virions are then released outside the cell through exocytosis, and will be taken up as lysosome-like structures by satellite cells or neurons. Neurons may spread the virus by three means:

  • Smooth-surfaced vesicle secretion at perikaryal specializations of neurons infecting satellite cells

  • Membrane-embedded spike protein secretions at axon end infecting neurons

  • Free particles diffusion infecting neurons and glial cells

In this manner, the virus can enter cells which do not even express the appropriate receptors. (Dubé et al. 2018; Li et al. 2020).

A study published in 2008 describes SARS-CoV infection of mice transgenic for human ACE2 (hACE2), in which the virus enters the brain primarily through the olfactory bulb. This resulted in dysfunction and death of neurons in cardiorespiratory centres in the medulla. Interestingly, very little infection was detected in the lungs, and extensive neuronal infection appeared to be the main cause of death (Netland et al. 2008).

Recent literature suggests that nasal epithelium may be a major source of viral RNA after COVID-19 infection, based on experiments on macaques, cats and ferrets. Moreover, the paper reveals the ability of SARS-CoV-2-positive cells to transverse the olfactory epithelium, and suggests the sustentacular cells as primary targets for infection (Cooper et al. 2020). The SARS-CoV-2 infection may subsequently spread to the brain, either through regions possessing a first-order connection with the olfactory bulb, or through the CSF. The infection may further escalate to other brain regions depending on the expression levels of the ACE-2 receptor (Wu et al. 2020a). Loss of olfaction is an early symptom, and this implies that the olfactory bulb may be the primary affected area in the brain (Baig et al. 2020).

Degeneration of olfactory bulb neurons has been observed in patients with persistant COVID-19 olfactory dysfunction (Kandemirli et al. 2021). The loss of olfaction may be due to the loss of neurons in the olfactory region (Gupta et al. 2020b). The NTS and neurons in medulla control the involuntary function of the lungs, and the presence of ACE2 receptors in this region makes it vulnerable to COVID-19 infection. Infection and subsequent death of neurons in NTS may lead to the failure of lung movement, leading to difficulty in breathing- a major symptom of COVID-19 (Li et al. 2020).

6 SARS CoV-2 and the blood-retinal barrier

Five types of neurons are present in the retina-ganglion cells, amacrine cells, bipolar cells, horizontal cells and photoreceptors (rods and cones). Light is absorbed by photoreceptor cells which transfer the signal to bipolar cells, and further to ganglion cells. Retinal ganglion cells convey these signals to the CNS through the optic nerve. The blood-retinal barrier (BRB) protects the retina, and helps maintain a balanced retinal environment for optimal visual function. The BRB is essentially an extension of the blood-brain barrier (BBB) (Purves et al. 2001; Cunha-Vaz et al. 2011).

The BRB is divided into two modules: inner BRB (iBRB) and outer BRB (oBRB). The BRB is a barrier which regulates the movement of molecules and fluids into the retina. It also prevents leakage of harmful agents and macromolecules into the retina. The iBRB is established by tight junctions (TJs) between the retinal endothelial cells underlying retinal capillaries. The oBRB is established by the TJs between neighbouring retinal pigment epithelial (RPE) cells, and serves to separate the choroidal system from the sensory retina. The oBRB protects the neuroretina from blood-borne pathogens. Alterations in the BRB play a very important role in the development of retinal diseases. The two most common retinal diseases are age-related macular degeneration (AMD) and diabetic retinopathy (DR). These two diseases are caused by changes in BRB (Purves et al. 2001).

Several factors cause inflammation in the retina, leading to disease. Bacteria, viruses, parasites and fungi are capable of breaching the BRB and infecting retina. This may cause inflammation and ocular infections like conjunctivitis, endophthalmitis, and keratitis which are most commonly caused by bacteria and viruses (Singh et al. 2017; Belyhun et al. 2018).

RNA viruses such as Dengue virus, Chikungunya and Zika virus (ZIKV) are known to have ocular manifestations. Previous studies have demonstrated that direct inoculation of ZIKV in mouse eye makes the BRB, RPE layer and retinal endothelium highly permeable, and also induces cell death. In adults, this virus causes retinal edema and retinal hemorrhages (Singh et al. 2017; Donoso Mantke et al. 2018; Manangeeswaran et al. 2018). Dengue virus also infects the retina and the cells lining the BRB, causing dengue retinopathy, macular edema and retinal vasculopathy. The mechanism of dengue retinopathy is poorly understood, but dengue patients show loss of RPE cells and decrease in the integrity of epithelial barrier (Donoso Mantke et al. 2018). The murine coronavirus, mouse hepatitis virus (MHV) causes a biphasic retinal disease in mice. The viral RNA of MHV persists within the retina for a long time and causes retinal degeneration. In one study, the viral RNA was detected in the inner and outer layer of retina, and also in ganglion cell layer within the retina, inducing apoptosis and leading to murine retinopathy (Komurasaki et al. 1996; Wang et al. 2000).

There are several types of CoV that are known to infect humans and animals. These CoV mainly affect the respiratory tract, but they may also affect ocular tissue. Patients infected with SARS-CoV-2 show ocular complications like conjunctivitis (Seah and Agrawal 2020a). Tears and conjunctival secretion from SARS-CoV-2 patients have been shown to contain viral RNA, and this viral RNA can further infect healthy persons (Ferner et al.). A recent report shows that out of 31 SARS-CoV-2-infected patients, 9 were severely affected, and the conjunctival secretion and tears samples tested positive for the virus by RT-PCR (Ferner et al.; Seah and Agrawal 2020b; Sun et al. 2020b). The summary of probable Coronavirus interactions and associated abnormalities in CNS and PNS is listed in table 2 and graphically represented in figure 2.

Table 2 CNS and PNS abnormalities observed in COVID-19 patients
Full size table
Figure 2
figure 2

Schematic of probable Coronavirus interactions and associated abnormalities in CNS and PNS. SARS-CoV-2 interacts with ACE2 receptors which are expressed by retinal pigment epithelial cells. This binding may affect the cell lining of BRB and cause inflammation in retina, resulting in conjunctivitis and other ocular abnormalities (left). The virus may also interact with sustentacular cells through ACE2 receptors in the olfactory system and lead to loss of olfaction (center). In the brain, the virus may attach to endothelial cells in BBB that express ACE2 receptors, and impair the endothelial barrier thereby gaining access to brain regions which may further cause cognitive impairment and memory loss (right).

Full size image

7 Clinical management of COVID-19 neurological manifestations

The incidence and complete clinical manifestations of COVID-19 effects on CNS is still not fully understood. Learnings from global scientific and clinical studies suggest that SARS-CoV-2 can invade the nervous system. However, when studied in totality, clinically-relevant direct CNS involvement has not been established. As per published reports, neurologic manifestations appear to be present in 36.4% to 69% of all COVID-19 patients requiring hospitalization (Mao et al. 2020b; Carod Artal 2020).

The manifestations observed in clinical settings included delirium, anosmia or abnormalities in smell and taste observed in almost all the patents suffering from COVID-19, headache in almost 70% of hospitalized patients, signs of corticospinal tract in 67% of patients, dizziness in 17% of patients and stroke in 5% of patients requiring hospitalization (Carod-Artal 2020; Helms et al. 2020; Mao et al. 2020a; Aaroe et al. 2020). Although SARS-CoV-2 may not infect CNS directly, the virus may increase risk of neurological disease (Xu et al. 2020a). The pathophysiology of these neurological manifestations is currently unknown, but possible mechanisms include hypoxia-mediated injuries (Kotfis et al. 2020; Asadi-Pooya 2020), systemic proinflammatory conditions (Nie et al. 2020), and possible blood-brain barrier disruption subsequent to SARS-CoV-2 binding to angiotensin-converting enzyme 2 (ACE2) (Cipriano et al. 2020).

SARS-CoV-2-related neurological manifestations can be broadly categorized into two different types based on their impact on the nervous system: Manifestations arising as a result of direct invasion of SARS-CoV-2 virus on the nervous system include anosmia, encephalitis and myelitis. The other type of manifestations include those occurring as a result of SARS-CoV-2 infection in other systems. This subset includes clinical manifestations such as stroke, seizures and status epilepticus, altered mental status (AMS) including delirium, headache and neuromuscular disorders.

7.1 Anosmia

Acute loss of smell (anosmia) and taste (ageusia) are early or initial symptoms post SARS-CoV-2 infection (Tong et al. 2020). A study including 2 million participants identified smell and taste as the strong predictors of COVID-19 (Menni et al. 2020). Almost all COVID-19 positive patients report anosmia or ageusia or both, either at onset of disease or during the early stages of disease progression (Kaye et al. 2020; Sayin et al. 2020). Anosmia is reported in patients without any symptoms of nasal congestion or rhinorrhea, indicating possible local inflammation. Infections of the upper respiratory tract are thought to be responsible for sudden acute onset of anosmia or ageusia in COVID-19 patients (Hummel et al. 2011; Giacomelli et al. 2020).

In a mouse model, the SARS-CoV virus penetrates through the olfactory bulb transneuronally resulting in rapid spread of the virus to connected neuronal areas (van Riel et al. 2015). The virus may inflict damage to the olfactory nerve during invasion and multiplication, thereby resulting in acute anosmia in almost all the patients studied during early stages of the disease progression (Perlman and McCray 2013; Politi et al. 2020). Associated ageusia in some cases might be a secondary manifestation of olfactory dysfunction. Moreover, ACE-2 receptor- the main host cell surface receptor facilitating the virus binding and entry to host cell, is widely expressed on the epithelial cells of the oral mucosa, and damage to mucosal epithelium may be responsible of ageusia in early stages of COVID-19 disease (Xu et al. 2020c).The neuroinvasive nature of COVID-19 is slowly emerging through recent studies demonstrating the presence of ACE2 in the mitral cells of olfactory bulb, olfactory sensory neurons (OSN) nuclei and cortical neurons in human brain organoids (Cooper et al. 2020). However, imaging of the olfactory system in COVID-19 patients showed normal tissue or only focal inflammation (Lechien et al. 2020a). Inflammatory intermediates may lower the expression of the olfactory receptors, and this may explain the pathophysiology underlying observed anosmia in COVID-19 patients.

Among COVID-19 patients, approximately 66–80% display anosmia, but demonstrate spontaneous improvement and reach a complete resolution of this symptom within 7–10 days from the clinical onset of disease (Vaira et al. 2020; Yan et al. 2020; Hopkins et al. 2020; Lechien et al. 2020b). Use of corticosteroids to treat anosmia are contraindicated since most subjects recover from the condition without clinical intervention (Lee and Chong 2020).

7.2 Encephalitis and myelitis

Some studies describe SARS-COV-2 patients with impaired consciousness also presenting with acute encephalitis. Several medical centres around the globe are reporting brain and CSF abnormalities (Carod-Artal 2020; De Felice et al. 2020; Huang et al. 2020; Bernard-Valnet et al. 2020; Gatto et al. 2020). Brain abnormalities were found in 37-62% of patients displaying neurologic symptoms and requiring MRI-based imaging. In a study on 13 encephalopathy patients with unclear etiology, 8 (62%) had leptomenengial enhancement (Helms et al. 2020). Out of this group, frontotemporal hypoperfusion was observed in all the 11 patients who underwent perfusion imaging. In another study, out of 27 patients admitted to ICU with neurologic symptoms, 37% demonstrated cortical abnormalities including 7 patients showing cortical diffusion restriction, 5 patients with subtle leptomeningeal enhancement and 3 patients with either subcortical or deep white matter signal abnormalities (Kandemirli et al. 2020).

Recent reports point to the fact that SARS-CoV-2 may also have neurotropic effects, with multiple COVID-19 patients presenting neurological symptoms along with common respiratory symptoms (Mao et al. 2020a). In a case study from Japan, SARS-CoV-2 RNA was detected in CSF of a patient suffering from clinically defined meningoencephalitis (Moriguchi et al. 2020). In another case study, a patient with clinically proven SARS-CoV-2 infection was CSF-negative for bacteria, herpes simplex virus type 1 and 2, varicella zoster virus, and West Nile virus. However, hemorrhagic ring enhancing lesions a characteristic of acute necrotizing encephalitis were observed in the bilateral thalami, medial temporal lobes and sub-insular regions (Poyiadji et al. 2020). Case reports such as these may have led to the popular belief that SARS-CoV-2 causes acute necrotizing encephalitis due to a ‘cytokine storm’ and that the virus need not directly infect the brain or CSF to cause these neurologic manifestations (Savarin and Bergmann 2018; Sun et al. 2020a; Balloy et al. 2020).

In terms of management of encephalitis, screening is first carried out to look for clinical features such as headache, nuchal rigidity, photophobia and altered conscious levels. Subsequently, CT/MRI-based imaging is performed to diagnose structural etiologies or vessel occlusion. In case of acute encephalitis, lumbar puncture is advised and the CSF is screened for presence of virus including SARS-CoV-2 (Tsivgoulis et al. 2020; Filatov et al. 2020; Poyiadji et al. 2020; Haddad et al. 2020). As a clinical management strategy, patients with suspected encephalopathy are treated with anti-infectives such as Ceftriaxone, Vancomycin and Acyclovir. These can be discontinued in lieu of specific treatment once the viral or bacterial processes are cleared during the clinical work-up mentioned above (McLaren et al. 2020; Murphy and Pardo 2020; Francis and Parsh 2020; Chong et al. 2020). In case of patients with acute necrotizing encephalitis along with unusual IL-6 elevation, Tocilizumab was found to demonstrate favorable clinical outcomes (Bilbul et al. 2020; Toniati et al. 2020).

7.3 Cerebrovascular disease and stroke

COVID-19 patients suffering from cerebrovascular disease are vulnerable to stroke as a result of a systemic inflammatory and prothrombotic state (Vonck et al. 2020). In some estimates, 4–5% of SARS-CoV-2-infected patients may suffer from stroke (Zhao et al. 2020; Tejada Meza et al. 2020; Morassi et al. 2020). Among such cases, ischaemic stroke is more prevalent than intracerebral hemorrhage or cerebral venous sinus thrombosis. Associated factors include co-morbidities like hypertension, diabetes or prior cerebrovascular disease (Moshayedi et al. 2020). Biochemical factors like elevated C-reactive protein and elevated D-dimer also result in stroke among patients suffering from severe SARS-CoV-2 infection (Yaghi et al. 2020; Tsushima et al. 2020; Xu et al. 2020b; Sato et al. 2020; Reddy et al. 2020).

The exact pathophysiology of stroke is still not clearly understood. But some conclusions can be drawn with respect to the association of cerebrovascular disease with the onset of COVID-19 infection. As mentioned earlier, studies have suggested that SARS-CoV-2 can exploit axonal transport to infect the brain via the cribriform plate and olfactory bulb (Tsivgoulis et al. 2020; Ellul et al. 2020). It has been clearly demonstrated that SARS-CoV-2 virus internalization is dependent on expression of ACE-2 on the cell surface. SARS-CoV-2 induces a down-regulation of ACE-2, which is predominantly expressed in cells, and tissues of the respiratory system, gastrointestinal tract and brain. This down-regulation of ACE-2 results in over-activation of Renin Angiotensin System (RAS) and simultaneous down-regulation of downstream alternative RAS signaling in the brain (Helms et al. 2020; Montalvan et al. 2020). Concomitant vasodilation, neuro-inflammation and thrombogenesis may lead to stroke in the brain during SARS-CoV-2 infection (Serrano-Castro et al. 2020).

As a clinical management strategy, tissue Plasminogen Activator (tPA) is administered intravenously for stroke resulting from SARS-CoV-2 infection (Hess and Fagan 2010). In tPA-naïve patients with high risk of bleeding, Aspirin is administered as a part of anti-coagulative therapy. Also, high-intensity statins like Atorvastatin can be administered to stabilize the patient (Tuttolomondo et al. 2016; Zhang et al. 2019; Amarenco et al. 2019). Finally, if clinically appropriate, treatment of deep vein thrombosis can be considered (Ha et al. 2020).

7.4 Altered mental status and delirium

Delirium is one of the most common neurologic symptoms observed in COVID-19 patients (Kotfis et al. 2020; Beach et al. 2020). Moreover, hyperactive delirium characterized by waxing and waning arousal and impaired attention is observed in many SARS-CoV-2 positive patients, which is worsened due to isolation and excessive use of PPE (Sher et al. 2020). Nearly 66% of patients diagnosed with positive SARS-CoV-2 infection present some form of altered mental status including delirium (Hosseini et al. 2020). Given the complex nature of the manifestation, not much is known about the pathophysiology of delirium in COVID-19 infected patients. Delirium is not age restricted and equally affects the old and young population of SARS-CoV-2-positive patients (Palomar-Ciria et al. 2020; Beach et al. 2020).

The pathophysiology of the different cognitive and behavioural deficits in infected patients needs to be studied. Aberrant expression of the neurotransmitter nitric oxide (NO) may be associated with neuropathological conditions related to COVID-19. Angiotensin II which is upregulated in these patients reportedly decreases production of NO, and thus its concentration in the brain. This may result in the neuropathological conditions associated with COVID-19, although further experimental data is needed for confirmation (Annweiler et al. 2020).

Clinically hyperactive delirium is managed by administration of antipsychotics and sedatives (Kotfis et al. 2020), but their usage is still debatable as far as the first line medication of choice is concerned (Rogers et al. 2020). Current clinical practice is to initiate pharmacological intervention with low dosage of sedative lorazepam or haloperidol and subsequently escalate the dose if needed (Shrikant Kulkarni 2018; March et al. 2019). However, benzodiazepines are contradicted as a therapy for COVID-19-related delirium since it may cause respiratory depression (Gupta et al. 2020a).

8 Conclusions

There is now sufficient evidence available about how the Coronavirus affects the respiratory system leading to fever, cough, cold and breathing problems. However, coronaviruses also affect the CNS and PNS. The presence of virus in CNS and PNS is associated with early or delayed onset of neurological symptoms such as headache, dizziness, seizures, impaired consciousness, loss of smell, conjunctivitis and ocular abnormalities. Nevertheless, these neurological symptoms are not common in COVID-19 outbreaks. Patients presenting with neurological symptoms appear to be fewer in number compared with those presenting with respiratory distress. Identifying neurological problems such as stroke and encephalitis is crucial since they can cause lifetime disability and these patients may require long-term care. Assessment of CNS-related abnormalities should be included for patients who are COVID-19 positive for collecting evidence to piece together the mode of action of the virus in causing neurological distress. Further investigations on the mode of entry of this virus into specific regions of the brain and retina would also be useful to understand the CNS connections of SARS-CoV-2. These studies will help alleviate the global health burden due to the novel Coronavirus, as well as address the social and economic costs due to neurological complications in COVID-19 patients.